Table 4 Sleep quality of patients with or without NAB.

From: Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial

N = 39

Group

Baseline

After treatment

P-value

PSQI

NAB

13.5 (7.3, 15.0)

11.0 (5.3, 16.0)

0.162

Non-NAB

10.0 (8.0, 14.0)

6.0 (4.0, 8.0)

 < 0.001

Subjective sleep quality

NAB

2.0 (1.0, 2.0)

1.0 (1.0, 2.0)

0.152

Non-NAB

2.0 (1.0, 2.0)

1.0 (1.0, 1.0)

 < 0.001

Sleep latency

NAB

1.0 (1.0, 3.0)

1.0 (1.0, 2.0)

0.998

Non-NAB

1.0 (0.0, 2.0)

1.0 (0.0, 1.0)

0.031

Sleep duration

NAB

2.0 (1.0, 2.8)

2.0 (1.0, 2.0)

 > 0.999

Non-NAB

2.0 (1.0, 2.0)

1.0 (1.0, 2.0)

0.031

Habitual sleep efficiency

NAB

1.0 (0.0, 2.8)

1.0 (0.0, 3.0)

 > 0.999

Non-NAB

1.0 (0.0, 3.0)

0.0 (0.0, 2.0)

0.004

Sleep disturbance

NAB

2.0 (1.0, 5.8)

1.5 (1.0, 5.8)

0.655

Non-NAB

2.0 (1.0, 2.0)

1.0 (1.0, 1.0)

0.002

Used sleep medication

NAB

0.0 (0.0, 0.0)

0.0 (0.0, 0.0)

0.250

Non-NAB

0.0 (0.0, 1.0)

0.0 (0.0, 0.0)

0.063

Daytime dysfunction

NAB

2.0 (1.3, 3.0)

1.5 (0.0, 3.0)

0.322

Non-NAB

2.0 (0.0, 3.0)

0.0 (0.0, 2.0)

0.027

  1. PSQI: Pittsburgh Sleep Quality Index; NAB: nocturnal acid-breakthrough.